Overview

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

The main objective of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess the impact of maintenance orteronel on disease progression and hence on quality of life in patients with metastatic castration-resistant prostate cancer who have achieved at lease disease stabilization after first line chemotherapy with docetaxel.

Phase:

Phase 3

Details

Lead Sponsor:

Swiss Group for Clinical Cancer Research

Treatments:

Docetaxel